Evidence map›Paper›PMID 31285189›Full record

ArticleBlood advances2019

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.

Allison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, Mark Bishton, Chris van Vliet, Pedro Farinha, Clare Gould, Simone Birch, Laurie H Sehn, Vishakha Sovani and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Trial
  5. Article
  6. High-grade B-cell lymphomas: high difficulties to diagnose and treat?Hematology. American Society of Hematology. Education Program · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Allison BarracloughDepartment of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Musa AlzahraniDepartment of Hematology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Marianne Schmidt EttrupDepartment of Pathology, Aalborg University Hospital, Aalborg, Denmark.
Mark BishtonDepartment of Haematology, Nottingham City Hospital, Nottingham, United Kingdom.ORCID 0000-0001-6058-1036
Chris van VlietDepartment of Anatomical Pathology, PathWest QEII Medical Centre WA, Perth, WA, Australia.
Pedro FarinhaDepartment of Pathology and Laboratory Medicine and Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada.ORCID 0000-0001-9364-9391
Clare GouldTranslational Research Institute, University of Queensland Diamantina Institute, Brisbane, QLD, Australia.ORCID 0000-0002-3043-9503
Simone BirchDepartment of Anatomical Pathology, Pathology Queensland, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Laurie H SehnCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada.
Vishakha SovaniHaematology Malignancy Diagnostic Service, Nottingham City Hospital, Nottingham, United Kingdom.
Mitchell Steven WardDepartment of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Bradley AugustsonDepartment of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Jorne BicclerDepartment of Haematology, Aalborg University Hospital, Aalborg, Denmark.
Joseph M ConnorsCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada.
David W ScottCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada.
Maher K GandhiUniversity of Queensland Diamantina Institute, Brisbane, QLD, Australia.ORCID 0000-0003-1000-5393
Kerry J SavageCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada.
Tarec El-GalalyDepartment of Haematology, Aalborg University Hospital, Aalborg, Denmark.ORCID 0000-0002-4406-380X
Diego VillaCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada.ORCID 0000-0002-4625-3009
Chan Yoon CheahDepartment of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia.ORCID 0000-0001-7988-1565

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In advanced-stage diffuse large B-cell lymphoma (DLBCL), the presence of an activated B-cell phenotype or a non-germinal center (GCB) phenotype, coexpression of MYC and BCL2 by immunohistochemistry, and the cooccurrence of

Indexed as

Biomarkers, TumorAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCell Transformation, NeoplasticCyclophosphamideDoxorubicinFemaleHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingPositron Emission Tomography Computed TomographyBCL2 protein, humanBiomarkers, TumorCyclophosphamideDoxorubicinMYC protein, humanPrednisoneProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycR-CHOP protocolRituximabVincristine

Identifiers

PMID31285189
PMCPMC6616265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.